

## ***Clinical Utilization Management Guidelines***

The *Clinical Utilization Management (UM) Guidelines* on this list represent the *Clinical UM Guidelines* adopted by the Medical Operations Committee for the Government Business Division effective August 24, 2017.

To see the full list of *Clinical UM Guidelines*, visit the [Medical Policies and Clinical UM Guidelines](#) page.

**Note:** CG-DRUG-29 Hyaluronan Injections in the Knee will be implemented as investigational and not medically necessary on December 1, 2017.

<b>Guideline number</b>	<b><i>Clinical UM Guideline name/title</i></b>
CG-DRUG-01	Off-Label Drug and Approved Orphan Drug Use
CG-DRUG-03	Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis
CG-DRUG-04	Use of Low Molecular Weight Heparin Therapy, Fondaparinux (Arixtra <sup>®</sup> ) and Direct Thrombin Inhibitors in the Outpatient Setting
CG-DRUG-05	Recombinant Erythropoietin Products
CG-DRUG-08	Enzyme Replacement Therapy for Gaucher Disease
CG-DRUG-09	Immune Globulin (Iq) Therapy
CG-DRUG-11	Infertility Drugs
CG-DRUG-13	Hepatitis B Interferon Antiviral Therapy
CG-DRUG-14	Dihydroergotamine Mesylate (DHE) Injection for the Treatment of Migraine or Cluster Headaches in Adults
CG-DRUG-16	White Blood Cell Growth Factors
CG-DRUG-18	Nesiritide (Natrecor <sup>®</sup> )
CG-DRUG-19	Progesterone Therapy as a Technique to Prevent Preterm Delivery in High-Risk Women
CG-DRUG-20	Enfuvirtide (Fuzeon <sup>®</sup> )
CG-DRUG-21	Naltrexone (Vivitrol <sup>®</sup> ) Injections for the Treatment of Alcohol and Opioid Dependence
CG-DRUG-24	Repository Corticotropin Injection (H.P. Acthar <sup>®</sup> Gel)
CG-DRUG-25	Intravenous versus Oral Drug Administration in the Outpatient and Home Setting
CG-DRUG-27	Clostridial Collagenase Histolyticum Injection
CG-DRUG-28	Alglucosidase alfa (Lumizyme <sup>®</sup> )
<b>CG-DRUG-29</b>	<b>Hyaluronan Injections in the Knee</b>
CG-DRUG-31	Oncology Drug Treatment Regimens for Adults <b>Note:</b> At this time, this guideline is not implemented for medical benefit determinations.
CG-DRUG-33	Palonosetron
CG-DRUG-34	Docetaxel (Docefrez <sup>™</sup> , Taxotere <sup>®</sup> )

<https://medproviders.anthem.com/ky>

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Anthem Kentucky Managed Care Plan, Inc., independent licensee of the Blue Cross and Blue Shield Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. WEBPAKY-0108-17 October 2017



CG-DRUG-38	Pemetrexed Disodium (Alimta <sup>®</sup> )
CG-DRUG-40	Bortezomib (Velcade <sup>®</sup> )
CG-DRUG-41	Zoledronic Acid
CG-DRUG-42	Asparagine Specific Enzymes (Asparaginase)
CG-DRUG-43	Natalizumab (Tysabri <sup>®</sup> )
CG-DRUG-44	Pegloticase (Krystexxa <sup>®</sup> )
CG-DRUG-45	Octreotide acetate (Sandostatin <sup>®</sup> ; Sandostatin <sup>®</sup> LAR Depot)
CG-DRUG-46	Fosaprepitant (Emend <sup>®</sup> )
CG-DRUG-47	Level of Care: Specialty Pharmaceuticals
CG-DRUG-48	Azacitidine (Vidaza <sup>®</sup> )
CG-DRUG-49	Doxorubicin Hydrochloride Liposome Injection
CG-DRUG-50	Paclitaxel, protein-bound (Abraxane <sup>®</sup> )
CG-DRUG-51	Romidepsin (Istodax <sup>®</sup> )
CG-DRUG-52	Temsirolimus (Torisel <sup>®</sup> )
CG-DRUG-53	Drug Dosage, Frequency, and Route of Administration
CG-DRUG-54	Agalsidase beta (Fabrazyme <sup>®</sup> )
CG-DRUG-55	Elosulfase alfa (Vimizim <sup>®</sup> )
CG-DRUG-56	Galsulfase (Naglazyme <sup>®</sup> )
CG-DRUG-57	Idursulfase (Elaprase <sup>®</sup> )
CG-DRUG-58	Laronidase (Aldurazyme <sup>®</sup> )
CG-DRUG-59	Testosterone Injectable
CG-DRUG-60	Gonadotropin Releasing Hormone Analogs for the Treatment of Oncologic Indications
CG-DRUG-61	Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications
CG-DRUG-62	Fulvestrant (FASLODEX <sup>®</sup> )
CG-DRUG-63	Levoleucovorin Calcium (Fusilev <sup>®</sup> )
CG-DRUG-64	FDA-Approved Biosimilar Products